Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06846073

Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.

The goal of this clinical trial is to learn if the efficacy of dexamethasone implant combined with anti-VEGF superior to anti-VEGF monotherapy in the treatment of DME in Chinese patients. The main questions it aims to answer are:

1. Whether combination therapy improves the best corrected visual acuity at 6 months and 12 months? 2. Does combination therapy improve retinal anatomy better than monotherapy at each time point?

Researchers will compare the combination therapy to the monotherapy to see if dexamethasone implant combined with anti-VEGF will leads to better results.

Participants will:

1. be randomly assigned to one of two groups with equal probability to receive the combination of intravitreal anti-VEGF and dexamethasone implant injections or intravitreal anti-VEGF injections. 2. During the first 3 months, patients in both groups will receive monthly injections of anti-VEGF. In the double protocol group, the first dexamethasone implant injection will be administered simultaneously with the first loading dose of anti-VEGF injections. Between 4 and 12 months, patients will receive intravitreal anti-VEGF injections as needed/pro-re-nata (PRN). 3. Patients will have regular follow-up. Routine examination includes Central retinal thickness (CRT), intraocular pressure (IOP), slit lamp examination, best corrected visual acuity (BCVA) and OCT.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Diabetic Macular Edema (DME)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 1/type 2 diabetes mellitus with good glycaemic control and glycated haemoglobin ≤ 10.0%; DR stage II-III;
  • DME with involvement of the central concavity and resulting in the patient's vision loss;
  • Central retinal thickness (CRT) ≥250 μm;
  • No refractive interval clouding and pupillary constriction affecting fundus examination;
  • No Pan-Retinal Photocoagulation treatment within 3 months before enrolment;
  • No macular laser treatment in the past or during the follow-up period;
  • Good patient cooperation and compliance.

Exclusion criteria

  • other macular lesions such as macular preexisting membranes, macular schisis, or other causes of macular oedema such as uveitis and central retinal vein occlusion;
  • Co-existence of diabetic optic neuropathy;
  • Previous intraocular injection therapy such as anti-VEGF drugs or glucocorticoid drugs in the target eye;
  • History of vitreoretinal surgery in the target eye;
  • A history of uncontrolled stable glaucoma or hypertension, hormonal hypertension in the target eye;
  • Aphakic eyes with posterior lens capsule rupture with an anterior chamber IOL (ACIOL), iris or transscleral fixed intraocular IOLs, and patients with posterior lens capsule rupture;
  • Pregnant or breastfeeding patients, uncontrolled hypertension within 3 months, cerebrovascular accident or myocardial infarction, uncontrolled diabetes mellitus, or other reasons for not being able to co-operate with the relevant examination;
  • Lost visits and data loss.

Treatment and study plan

The combination of intravitreal anti-VEGF and dexamethasone implants injections.

Combination Product

Early combination of intravitreal dexamethasone implant and anti-VEGF injection for the treatment of DME.

Primary outcomes

  1. Average change in best corrected visual acuity (BCVA) of each group from baseline to the end of month 6.

    Time frame: 6 month.

    BCVA was measured using the log Mar visual acuity chart or the ETDRS visual acuity chart.

Secondary outcomes

  1. Average change in best corrected visual acuity (BCVA) of each group from baseline to month 3, 12.

    Time frame: 3 month and 12 month

    BCVA was measured using the log Mar visual acuity chart or the ETDRS visual acuity chart.

  2. Average change in central retinal thickness (CRT) of each group from baseline to month 3, 6,12.

    Time frame: 3, 6 and 12 month

    Central retinal thickness (CRT) is a measurement of the macula from the internal limiting membrane to the RPE and can be quantified by OCT scans

  3. The proportion of eyes with a 5-letter /10-letter improvement from baseline of BCVA at month 6 and 12.

    Time frame: 6 month and 12 month

    BCVA was measured using the log Mar visual acuity chart or the ETDRS visual acuity chart.

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Collaborators

  • Jiaxing Hospital of T.C.M
  • Ningbo Eye Hospital

Registry information

Official study title

A Prospective Clinical Study on the Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of Diabetic Macular Edema (DME) in Naive Patients.

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Feb 25, 2025
Registry last updated
Feb 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.